Professional microneedling and nano-needling device launches in UK, Ireland, Germany, France, Spain and Portugal

The SkinStylus® SteriLock® MicroSystem

The SkinStylus® SteriLock® MicroSystem, a professional microneedling and nano-needling device, is now available in the UK, Ireland, Germany, France, Spain and Portugal.
The SkinStylus® SteriLock® MicroSystem, a professional microneedling and nano-needling device, is now available in the UK, Ireland, Germany, France, Spain and Portugal.

LONG BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — SkinHealth Systems (Nasdaq: SKIN), home to flagship brand Hydrafacial™, today announced the European expansion of the SkinStylus® SteriLock® MicroSystem, a professional microneedling and nano-needling device intended for cosmetic use. The device is now available in the UK, Ireland, Germany, France, Spain and Portugal.

The launch builds on growing global interest in professional microneedling and advances the SkinHealth Systems’ strategy to offer complementary solutions addressing a broad range of skin concerns, needs and treatment goals. The company will leverage Hydrafacial’s established European commercial organization and provider relationships to introduce SkinStylus to aesthetic professionals across the region.

“Expanding SkinStylus internationally is an important step in building SkinHealth Systems into a broader medical aesthetics ecosystem,” said Pedro Malha, president and chief executive officer of SkinHealth Systems. “By leveraging the strength of the Hydrafacial device footprint and our established provider relationships, we can bring providers complementary technologies that address a wider range of cosmetic skin concerns and create more opportunities to serve their clients.”

SkinHealth Systems acquired SkinStylus in 2023 to broaden its professional skin health portfolio beyond Hydrafacial treatments. Together, the technologies provide aesthetic professionals with distinct and complementary treatment options: Hydrafacial treatments help improve skin quality and support ongoing skin health maintenance, while SkinStylus microneedling and nano-needling treatments support the skin’s natural renewal process and help visibly rejuvenate its appearance.

Microneedling is a nonsurgical, minimally invasive cosmetic procedure performed by qualified providers using an array of fine needles to create controlled microchannels in the skin. The process helps support and refresh the skin and can help improve the appearance of fine lines and wrinkles, uneven texture, and overall skin quality, with minimal downtown.

Engineered for precision, consistency and practitioner confidence, SkinStylus features adjustable settings and multiple SteriLock cartridge options. This versatility allows trained aesthetic professionals to tailor treatments to each client’s cosmetic skin concerns, needs and desired outcomes. SkinStylus nano-needling treatments may also help enhance the absorption of professional topical skincare products applied as part of the treatment.

SkinStylus will be sold through SkinHealth Systems’ direct European commercial organization, with availability expected to expand into select distributor markets beginning in 2027.

About SkinHealth Systems
SkinHealth Systems (NASDAQ: SKIN) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial™, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus™ microneedling and HydraScalp™ with Keravive™, SkinHealth Systems combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide. Learn more at skinhealthsystems.com or follow us on LinkedIn. Local providers can be found at hydrafacial.com/find-a-hydrafacialist.

Forward-Looking Statements
Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding SkinHealth Systems Inc.’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside SkinHealth Systems Inc.’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Important factors that may affect actual results or outcomes include, among others: SkinHealth Systems Inc.’s ability to manage growth; SkinHealth Systems Inc.’s ability to execute its business plan; providers’ and consumers’ perception of SkinStylus; regulatory and other laws that may affect or impact the ability of SkinHealth Systems Inc. to sell SkinStylus in European countries and through distributor markets; the success of SkinStylus’ launch in Europe and how the products are received amongst providers and consumers in each respective country; potential litigation involving SkinHealth Systems Inc.; changes in applicable laws or regulations; the possibility that SkinHealth Systems Inc. may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2026 filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s subsequent filings with the SEC such as on a Quarterly Report on Form 10-Q. Those risks continue to be relevant to the Company’s performance and financial condition. Moreover, the Company operates in a very competitive and rapidly changing environment. New risk factors emerge from time-to-time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. SkinHealth Systems Inc. expressly disclaims any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Press: press@skinhealthsystems.com
Investors: IR@skinhealthsystems.com

Source: SkinHealth Systems

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/083387ad-8e79-4f77-a567-18cb069dd07c

Total Voting Rights

Shell plc (the “Company”) announces, in compliance with Rule 5.6.1 of the FCA’s Disclosure Guidance and Transparency Rules that, as at 30 September 2026 the Company’s capital consisted of 5,729,497,530 ordinary shares of €0.07 each, with voting rights. The Company held no shares in Treasury.

Accordingly, the total number of voting rights in the Company was 5,729,497,530. This figure may be used by shareholders as the denominator for the calculations by which they determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA Disclosure Guidance and Transparency Rules.

Enquiries

Shell Media Relations
International +44 (0)207 934 5550; U.S. and Canada: Contact form

ICEYE and Nokia partner to launch secure and sovereign satellite communications for governments and defense customers

  • Sovereign, dual-use satellite communications systems owned and operated by the nations that use them.

Helsinki, Finland – October 1, 2026 – ICEYE, the European leader in sovereign intelligence from space, and Nokia, a global leader in connectivity infrastructure, today announced a partnership to develop secure, sovereign and high-performance broadband low Earth orbit (LEO) satellite communications systems for governments, supporting missions from defense and border security to emergency services and disaster response. Built on trusted European technology, the jointly developed satellite communications systems will give nations ownership and control of the satellites, ground segment and terminals. The first communications satellites are expected to be launched in 2028.

When terrestrial networks are disrupted or compromised, defense forces, first responders and civil authorities risk losing access to the information and command systems they depend on. Governments therefore need resilient communications infrastructure that remains available under the most demanding conditions, and that they can fully own and control.

The jointly developed sovereign systems will deliver targeted, high-throughput, low-latency connectivity over priority mission areas. Designed to complement military and commercial networks rather than replace them, it will add reach, resilience and capacity, helping governments and defense organizations maintain critical connections wherever operations take place.

The partnership brings together ICEYE’s track record delivering sovereign satellite missions with Nokia’s extensive experience in secure networking technologies and growing defense portfolio. Together, the companies will integrate satellites, ground infrastructure and ruggedized end-user terminals to extend ICEYE’s sovereign intelligence from space business model to satellite communications.

Rafal Modrzewski, CEO and Co-founder of ICEYE, said: “Together with Nokia, we are building on our proven space intelligence expertise and delivering sovereign, high-performance satellite communications. Nations must be able to fully own and control their communications, without dependency on a foreign commercial operator’s terms of service. We delivered Poland its own radar satellite system in under a year. Partnering with Nokia lets us move at a similar speed for satellite communications, on the timelines nations need.”

Justin Hotard, President and CEO of Nokia, said: “Sovereign operations depend on the ability to sense, decide and act in real time. Physical AI makes that possible, but only with secure, resilient connectivity across land, sea, air and space. By bringing together Nokia’s trusted networks with ICEYE’s proven sovereign space capabilities, we will deliver a satellite communications capability—complementing existing terrestrial networks, and giving nations the situational awareness, connectivity, and control they need to operate with confidence in contested environments across all domains.”

Modrzewski and Hotard will take the stage at the Helsinki Security Forum on October 2 for a session titled “How to Salvage Europe’s Technological Sovereignty.”

About Nokia 
Nokia is a global leader in connectivity infrastructure, enabling the AI supercycle. We build networks that connect intelligence and deliver a comprehensive connectivity solution across fixed, mobile, IP, optical, core, and data center networks. With security by design, AI-driven innovation, and AI-optimized architecture, Nokia delivers trusted infrastructure that enables AI to scale and advances connectivity to secure a brighter world.

Media inquiries
Nokia Press Office
Email: Press.Services@nokia.com

About ICEYE
ICEYE is the world leader in sovereign intelligence from space. We deliver persistent monitoring capabilities to detect and respond to changes in any location on Earth.

ICEYE owns the world’s largest and most advanced SAR (synthetic aperture radar) satellite constellation. To our customers we provide intelligence with unmatched quality, latency and revisit times, in any weather, day or night. To governments who choose to operate their own constellation we provide this proven capability as a sovereign system.

ICEYE-built constellations serve customers in defense and intelligence, environmental monitoring, insurance and emergency management. We enable fast decisions that contribute to a safer future.

Natively European, founded in Finland. ICEYE operates globally with over 1,000 employees.

Media contact: press@iceye.com

FORESIGHT VENTURES VCT PLC
LEI: 213800R88MRC4Y3OIW86

TOTAL VOTING RIGHTS
1 OCTOBER 2026

In conformity with DTR 5.6.1R, the Company announces that, as at 30 September 2026, the Company’s issued share capital consists of 103,892,702 Ordinary Shares in issue.

There are no shares held in Treasury.

The total number of voting rights of the Company is 103,892,702. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to, their interest in the Company under the FCA’s Disclosure Guidance and Transparency Rules.

For further information please contact:
Company Secretary
Foresight Group LLP
Contact: Stephen Thayer Tel: 0203 667 8100

Investor Relations
Foresight Group LLP
Contact: Andrew James Tel: 0203 667 8181

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND

Information about securities repurchasing program
Regulated information
Issuer social denomination: Michelin – LEI 549300SOSI58J6VIW052
Types of securities: ordinary shares – Code ISIN FR001400AJ45
Date : October 1st, 2026

Issuer Name Issuer code Transaction
date
ISIN Code Daily total volume (in number of actions) Daily weighted average price of shares acquired Platform
Compagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 01.10.2026 FR001400AJ45 201 844 32.4236 euros Over-the-counter
Compagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 01.10.2026 FR001400AJ45 201 844 32.4236 euros Over-the-counter
Compagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 01.10.2026 FR001400AJ45 201 844 32.4236 euros Over-the-counter

Issuer Name Issuer code PSI
Name
Issuer Code Transaction date ISIN Code Unit Price Currency Quantity bought Platform Transaction reference number Buyback objective
Compagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 NATIXIS KX1WK48MPD4Y2NCUIZ63 01.10.2026 FR001400AJ45 32,4236 Euro 201 844 Over-the-counter 5309224 Cancellation
Compagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 BNP PARIBAS R0MUWSFPU8MPRO8K5P83 01.10.2026 FR001400AJ45 32,4236 Euro 201 844 Over-the-counter 5309224 Cancellation
Compagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 01.10.2026 FR001400AJ45 32,4236 Euro 201 844 Over-the-counter 5309224 Cancellation

Attachment

  • Wouter Stammeijer appointed Chief Financial Officer (CFO) effective 1 November
  • Vladimir Cibic appointed Chief Technology Officer (CTO) effective 1 November and nominated for appointment to the Board of Management
  • Piero Overmars nominated as new member of the Supervisory Board
  • KPN simplifies its leadership structure; HR to report to the CEO

KPN announces that Wouter Stammeijer will be appointed Chief Financial Officer (CFO) effective 1 November. Vladimir Cibic will succeed him and will be appointed Chief Technology Officer (CTO) effective 1 November. He will also be nominated for appointment to the Board of Management as of the 2027 Annual General Meeting (AGM) of Shareholders. In addition, the Supervisory Board will nominate Piero Overmars as a new member of the Supervisory Board.

Wouter Stammeijer has served on the Board of Management as Chief Operating Officer since 2023. Before that, he worked in Treasury and M&A at ING and, since joining KPN in 2010, held roles including Head of Investor Relations and Chief Strategy Officer. In recent years, he has made an important contribution to the execution and further development of KPN’s strategy. With his financial experience, executive background and extensive knowledge of KPN and the sector, he is well positioned to lead KPN’s Finance function and contribute to the further execution of its strategy.

Vladimir Cibic has worked at KPN since 2000 and has held various roles spanning IT, digitalization and customer experience for both Consumer and Business customers. As Chief Information Security Officer (CISO), he also had overall responsibility for KPN’s cybersecurity and digital resilience. His broad technological expertise and proven track record in leading digital transformations equip him to contribute to the ongoing transformation of the organization and the provision of secure digital services.

Vladimir Cibic will be nominated for appointment to the Board of Management as of the AGM in April 2027. At that time, the Supervisory Board also intends to reappoint Wouter Stammeijer and Chantal Vergouw (Chief Business Market) for a further four-year term.

Gerard van de Aast, Chair of the Supervisory Board: “Over the past few years, Wouter and Vladimir have proven themselves as decisive leaders with a deep understanding of KPN, our customers and our strategy. Their appointments reflect the strength of our internal talent development and give us confidence that KPN will continue to successfully create sustainable value for customers, employees and shareholders. Chantal has demonstrated strong leadership of our business segment in recent years, and we are pleased that she will continue in this role.”

Joost Farwerck, CEO and Chair of the Board of Management: “I am pleased that Wouter is taking on the CFO position and that we are welcoming Vladimir to the Board. With the reappointment of Chantal, we are ensuring her continued commitment to our business customers. With these appointments, we can immediately focus on further accelerating the execution of our plans. They all know the organization and the strategy well and have made a valuable contribution in recent years. I look forward to continuing our work together within the board.”

Simplified leadership structure        
KPN is simplifying its leadership structure and will continue with a five-member Board of Management. Effective 1 October, the Chief People Officer will report directly to the CEO. This will keep leadership, talent development, organizational development and culture firmly anchored at the highest level and closely aligned with KPN’s strategy.

Changes to the Supervisory Board        
The Supervisory Board will nominate Piero Overmars as a new member as of the 2027 AGM. Overmars serves on the supervisory boards of Dura Vermeer and Adyen, among others, and brings extensive experience in strategy, supervision and finance.

Gerard van de Aast: “With the nomination of Piero Overmars, we are strengthening the Supervisory Board’s expertise in governance, value creation and finance. His experience as an executive and supervisory board member will be a valuable addition to KPN.”

The Supervisory Board will nominate Herman Dijkhuizen, Frank Heemskerk and Ben Noteboom for reappointment. After twelve years on KPN’s Supervisory Board, Jolande Sap is not eligible for reappointment. Marga de Jager has indicated that she will not be available for reappointment at the end of her first term.

2027 AGM        
Further information on the proposed appointments and reappointments and the related remuneration arrangements will be included in the agenda and explanatory notes for the 2027 AGM. The proposed appointments and resolutions are subject to the customary procedures, including the required involvement of the Central Works Council and the AGM.

Formal disclosures:
Royal KPN N.V.
Head of IR: Matthijs van Leijenhorst
Inside information: Yes
Topic: KPN announces changes to Board of Management and Supervisory Board
01/10/2026
KPN-N

Attachment

Staged equipment-supply arrangement advances proposed Rare Gas Hub in Minnesota

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO. 596/2014 ON MARKET ABUSE, AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AND REGULATION (EU) NO. 596/2014 ON MARKET ABUSE.

LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR) (TSXV: PLSR) (OTCQB: PSRHF) (“Pulsar” or the “Company”), a primary helium company, is pleased to announce that, further to its announcements dated June 30, 2026 and August 3, 2026, it has signed, through its wholly-owned subsidiary, Pulsar Helium MN Inc., and accepted a proposal (the “Proposal”) from Chart Energy & Chemicals, Inc. (“Chart”), a wholly-owned subsidiary of Baker Hughes Company (“Baker Hughes”), which operates as dedicated segment of Baker Hughes following the July 2026 acquisition of Chart Industries, Inc. The Proposal represents the agreement contemplated in the Company’s August 3, 2026, announcement and establishes a staged framework for the supply of equipment for Pulsar’s proposed Rare Gas Hub in Minnesota for an aggregate value of $85.5 million paid in stages on achievement of applicable milestones under the Proposal before applicable taxes, duties, shipping, commissioning and other items or adjustments not included in the Proposal.

Summary

  • Pulsar has signed Baker Hughes’ firm Proposal to supply the equipment for:
    • A helium purification and liquefaction plant (and related equipment package) with helium liquification capacity of 861 liters per hour, equivalent to approximately 7.5 million liters of liquid helium annually at continuous nameplate operation (the “Helium Plant”)
    • A CO2 plant with 300-tonne-per-day CO2 capture capacity (CO2 storage and loading equipment to be addressed separately) (the “CO2 Plant”)
  • An upfront payment of US$5.025 million is payable upon signing and approval of TSX Venture Exchange (“TSXV”) which shall be satisfied from existing cash resources, and the next stage payment of US$8.55 million is scheduled for January 31, 2027, subject to further funding. See ‘Commercial Framework’ below for further details on the payment schedule.

Thomas Abraham-James, Director and CEO of Pulsar, commented: “Signing and accepting Baker Hughes’ Proposal is a major milestone for Pulsar and an important step in advancing our proposed Rare Gas Hub. The planned Plant has a nameplate capacity of approximately 7.5 million litres of liquid helium and over 100,000 tons of liquid CO2 annually, supporting our strategy to develop an industrial scale rare-gas processing infrastructure in Minnesota.”

Equipment Scope and Capacity

The Proposal outlines the supply of equipment for the Helium Plant and CO2 Plant. Certain additional components relating to the CO2 Plant, including CO2 storage and loading and site-support services, are outside the current equipment-supply scope and will be addressed separately.

At stated nameplate capacity, the helium system would produce approximately 7.5 million liters of liquid helium annually before operating allowances, equivalent to approximately 200 million standard cubic feet of gaseous helium per year.

Equipment manufacture is scheduled to take place over an approximate two-year period following receipt of the Milestone 2 payment. Certain equipment included in the Proposal and relating specifically to the helium liquefaction system has already been manufactured.

Proposed Lake County Site

Separately, the Company is progressing discussions regarding a prospective Plant site in Lake County, Minnesota. Any acquisition, lease or other arrangement for the site remains subject to definitive documentation, satisfactory due diligence, confirmation of site and utility suitability, and applicable permits and approvals. The Company will provide further information if and when definitive documentation is executed.

Commercial Framework

The Proposal sets an aggregate equipment-supply price of US$85.5 million, for the Helium Plant and CO2 Plant. The equipment-supply price does not represent the total installed cost of the Plant and excludes taxes, duties and tariffs, installation and commissioning, site infrastructure and interconnections, and certain other owner and third-party costs.

The First Payment totaling US$5,025,000 is payable upon signing and approval of TSXV, inclusive of an amount of US $750,000 payable under the existing Limited Notice To Proceed (“LNTP”). All LNTP amounts (totalling US$1,000,000, including the US$250,000 deposit previously paid) will be credited dollar-for-dollar against applicable price and milestone payments under the Proposal. The Company currently has cash resources of US$25.2 million. The Proposal remains subject to approval of TSXV. Payment of Milestone 2 of US$8.55 million, is scheduled for January 31, 2027. Payment of Milestone 2 will authorize Chart to commence procurement of long-lead items. If Milestone 2 is not paid by that date, the project will automatically enter a suspension period of up to 180 days, during which the reserved helium liquefaction equipment will remain protected in accordance with the Proposal. During the suspension period, Pulsar will have no obligation to pay Milestone 2, and no cancellation charge will arise solely from the suspension. At the end of the suspension period, the parties will seek to agree whether to proceed, amend the commercial arrangements or terminate the project.

The Company continues to advance financing alternatives for the remaining payments under the Proposal and the wider development costs of the Plant and intends to update shareholders as material arrangements are confirmed.

The remaining milestones are tied to defined engineering, procurement, manufacture and delivery-readiness activities. They include issuance of piping and instrumentation diagrams (“P&IDs“) for hazard and operability study review; placement of orders for the pre-treatment and column major materials; issuance of P&IDs for manufacturing; confirmation that all major equipment is ready for shipment; and Chart’s submission of final documentation. Payments are scheduled against achievement of these milestones in accordance with the agreed project timetable, and combined comprise the full US$85.5 million contract value.

Cancellation Provisions

If Pulsar elects to terminate the Proposal for convenience, cancellation payments would be determined by the stage of work completed, ranging from 0% at project award to a maximum of 70% of the total contract value following Chart’s delivery of final project documentation. No cancellation payment would arise in respect of a milestone unless the associated milestone payment had become due and been paid by Pulsar.

Remaining Project Work

Development of the Plant remains subject to, among other matters, financing, payment of the applicable milestones under the Proposal, detailed engineering and EPC work, verification and testing of the equipment, definitive site arrangements, site development, receipt of required permits and regulatory approvals, installation and successful commissioning.

On behalf of Pulsar Helium Inc.
“Thomas Abraham-James”
CEO and Director

Further Information:

Pulsar Helium Inc.
connect@pulsarhelium.com
+ 1 (218) 203-5301 (USA/Canada)
+44 (0)2033 55 9889 (United Kingdom)
https://pulsarhelium.com
https://ca.linkedin.com/company/pulsar-helium-inc.

Strand Hanson Limited
(Nominated & Financial Adviser, and Broker)
Ritchie Balmer / Rob Patrick
+44 (0) 207 409 3494

Velocity Public Affairs
(Public Relations)
Stephanie Moncada / Mike Zipko
+ 1 (218) 203-5301
pulsarhelium@velocitypublicrelations.com

Yellow Jersey PR Limited
(Financial Public Relations)
Charles Goodwin / Annabelle Wills
+44 777 5194 357
pulsarhelium@yellowjerseypr.com

About Pulsar Helium Inc.

Pulsar Helium Inc. is a publicly traded company quoted on the AIM market of the London Stock Exchange (United Kingdom) and listed on the TSX Venture Exchange with the ticker PLSR (Canada), as well as on the OTCQB with the ticker PSRHF (United States of America). Pulsar’s portfolio consists of its flagship Topaz helium project in Minnesota, the Falcon project in Michigan (both in the USA), and the Tunu helium project in Greenland. Pulsar is the first mover in these locations with primary helium occurrences not associated with the production of hydrocarbons identified at both Topaz and Tunu.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to the Company’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements. Forward-looking statements herein include, but are not limited to, statements relating to the Company’s proposed Rare Gas Hub and the Plant, including the proposed operation, capacity, production, performance and commissioning of the same; the Company’s ability to make the applicable milestone payments under the Proposal and the timing and performance of the work contemplated by the Proposal; the receipt of TSXV approval of the Proposal and the satisfaction of the upfront payment from existing cash resources; the stated design capacity of the Helium Plant of 861 liters per hour and the equivalent annual production of approximately 7.5 million liters of liquid helium, or approximately 200 million standard cubic feet of gaseous helium, at continuous nameplate operation; the stated capture capacity of the CO2 Plant of 300 tonnes per day and the anticipated annual production of over 100,000 tons of liquid CO2; the commencement of procurement of long-lead items following payment of Milestone 2; the Company’s intention to advance financing alternatives for the remaining payments under the Proposal and wider development costs of the Plant and to update shareholders as material arrangements are confirmed; the timing of the Milestone 2 payment and subsequent milestone payments; the crediting of the LNTP deposit and LNTP payment against amounts payable under the Proposal; the suspension provisions and their operation; the cancellation provisions and the amount of any cancellation payments; the Company’s discussions regarding a prospective Plant site in Lake County, Minnesota; and the remaining work required to develop the Plant, including detailed engineering and EPC work, site development, permitting, installation and commissioning. Forward-looking statements may involve estimates and are based upon assumptions made by management of the Company, including, but not limited to, the Company’s capital cost estimates, management’s expectations regarding the availability of capital to fund the Company’s future capital and operating requirements; the ability to obtain all requisite regulatory approvals, including TSXV approval of the Proposal; Chart’s ability to deliver the equipment in accordance with the project timetable contemplated by the Proposal; the equipment meeting the stated design specifications and performance targets; and the Company’s ability to secure a suitable Plant site and related infrastructure on acceptable terms.

Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, that Pulsar may be unable to obtain sufficient financing or make the applicable milestone payments under the Proposal, which could result in the suspension, delay or termination of the project; the risk that, following any suspension period, the parties may not agree to proceed with or amend the commercial arrangements; the risk that cancellation payments may become payable if Pulsar elects to terminate for convenience; the risk that the total installed cost of the Plant, including taxes, duties, tariffs, installation, commissioning, site infrastructure and other costs excluded from the equipment-supply price, may be materially higher than anticipated; the risk that Pulsar may be unsuccessful in negotiating and executing a definitive agreement for the proposed Lake County site or securing the required land rights, electrical service, natural gas service and other infrastructure on acceptable terms; the risk that the equipment to be supplied under the Proposal may not meet the anticipated condition, performance, completion or project-specific requirements; or may not perform as anticipated or at all; the risk that actual lead times may differ materially from those contemplated by the Proposal due to supply chain constraints, manufacturing delays or other factors; the risk that actual production capacity, product purity and recovery rates may differ materially from stated design specifications; the risk that the requisite state rulemaking, environmental review, permitting and implementation steps will not be completed or will be delayed; the risk that TSXV approval may not be obtained on the anticipated timeline or at all; market conditions for helium and CO2 products; and other factors set forth above as well as risk factors included in the Company’s Annual Information Form dated February 3, 2026, for the year ended September 30, 2025, found under Company’s profile on www.sedarplus.ca.

Forward-looking statements contained in this news release are as of the date of this news release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. No assurance can be given that the forward-looking statements herein will prove to be correct and, accordingly, investors should not place undue reliance on forward-looking statements. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

ZUG, Switzerland, October 1, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on October 1, 2026. This 5-year campaign aims to accelerate research breakthroughs, improve access to care, and create a future where no one lives with the uncertainty of multiple sclerosis (MS). By bringing together people affected by MS, researchers, healthcare leaders, advocates, and supporters, the campaign seeks to translate scientific progress into meaningful advances in treatment and care, while strengthening the resources and support available to the MS community. Oculis’ sponsorship reflects a shared commitment to advancing innovation, addressing unmet needs, and improving the lives of people affected by MS.

As part of the campaign, the National Multiple Sclerosis Society is convening respected MS thought leaders, health industry and corporate leaders, researchers, and healthcare providers across three programs: a CEO Roundtable, Big Bets for Breakthroughs: The MS Research Symposium, and the Campaign to End MS Gala.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said, “Our sponsorship of the National MS Society’s Campaign to End MS marks the beginning of what we believe will be a long-term partnership with an organization that has spent 80 years advancing research and care for people living with MS. We share the Society’s commitment to accelerating progress for people affected by MS and, through our Privosegtor development program, we are working to advance a much-needed neuroprotective treatment option for patients experiencing optic neuritis and acute MS relapses.”

Oculis is currently developing Privosegtor with the aim to provide the first neuroprotective therapy for optic neuritis (ON), a common MS relapse type and often the first manifestation of MS, with broad potential applicability in other neuro-ophthalmic and neurological diseases. Following the successful Phase 2 ACUITY trial, Oculis launched the PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON. In addition, following positive pre-IND FDA feedback supporting Privosegtor’s development strategy for treating acute MS relapses, Oculis is on track to submit the related IND in the fourth quarter of this year. The Company plans to host an R&D Day in Q4 to provide updates on its pipeline and development programs, including Privosegtor.

– Ends –

About Privosegtor
Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina, including GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis, and multiple sclerosis (MS), where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility (clinical function disability) in the MS model.

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) as well as Orphan Drug designation from both the FDA and the EMA for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION). Building on the ACUITY Phase 2 dataset in ON and constructive FDA pre-IND feedback, Oculis is also planning an IND submission for Privosegtor for the treatment of acute MS relapses.

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.

About MS

MS is a chronic immune-mediated disease affecting approximately 2.8 million people worldwide, including around 850,000 in the U.S. alone.1-3 It is currently managed using immunomodulators or disease-modifying therapies (DMTs) that reduce the rate of relapses and therefore related relapse-associated worsening (RAW). However, relapses still persist for many patients, with an estimated 170,000 MS relapses occurring each year in the U.S.4 During an acute relapse, neurologists commonly use a short course of high-dose corticosteroids to reduce inflammation and shorten the episode, as is also standard of care in optic neuritis. However, corticosteroids do not mitigate the long-term disability, and recovery from relapses is often incomplete, such as in optic neuritis. There are currently no neuroprotective therapies approved for MS relapses, and there remains an urgent unmet medical need for treatments that can prevent central nervous system damage.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

About the National Multiple Sclerosis Society
The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives.
               
Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotection therapy for optic neuritis and its potential broad applicability across neurology, including in acute MS relapses, the initiation, enrollment, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Results of earlier stage clinical trials may not be replicated in subsequent clinical trials. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

  1. MS National Society
  2. Wallin et al., 2019, The prevalence of MS in the United States: A population-based estimate using health claims data – PubMed
  3. McGinley et al., 2021, Diagnosis and Treatment of Multiple Sclerosis: A Review – PubMed

Multiple sources on relapse rate (ARR) including: Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study – PubMed

Reykjavík, Oct. 01, 2026 (GLOBE NEWSWIRE) —

Amaroq Ltd.
(“Amaroq” or the “Company”)

2026 Nanoq Drilling Programme Completed and Initial Positive Metallurgical Test Work Results

1 October 2026 – Amaroq Ltd. (LSE and NASDAQ Iceland: AMRQ, OTCQX: AMRQF), an independent mine development company focused on unlocking Greenland’s mineral potential, is pleased to announce the completion of its 2026 resource drilling programme at the Nanoq Gold Project in South Greenland, alongside successful metallurgical test work results of Nanoq mineralisation, in relation to future processing at the Nalunaq facility. The Company has also commenced development of limited site infrastructure at Nanoq.

Highlights

  • 2026 drilling completed: 4,728.9 metres of core drilling across 33 holes, focussed on infill drilling of the Central Zone, to support a planned maiden Mineral Resource Estimate, together with step-out drilling to the south and at the West 1 target.
  • Strong visual indications: Visible gold and copper sulphides, similar to that observed in 2024 and 2025, have been identified with approximately 88% of holes intersecting visible mineralisation. Assay results remain pending.
  • Positive metallurgical test-work: Test work undertaken by SGS Lakefield indicates that Nanoq mineralisation is amenable for processing at the Nalunaq facility. Overall total gold recoveries using the existing flow-sheet of approximately 97–99%.
  • Infrastructure development underway: Construction has commenced on the Nanoq beach landing facility and starter access track, improving access to the mineralised area, supporting potential bulk sampling and future resource drilling.

Eldur Ólafsson, CEO of Amaroq, commented:
“The completion of this year’s drilling at Nanoq marks another important step in advancing the project towards a maiden Mineral Resource Estimate. We have significantly increased the geological information across the Central Zone, while continuing to test the broader potential of the system to the south and at West 1.

“The metallurgical results are also very encouraging, demonstrating strong gold recoveries using a flowsheet consistent with that at Nalunaq. This supports our strategy of evaluating Nanoq as a future source of material for processing at Nalunaq. Together with the new infrastructure, these results provide the basis for bulk sampling Nanoq ore at Nalunaq towards the end of 2027 or into 2028 and further resource and exploration drilling, as we continue to de-risk Nanoq’s full development potential.”

Assay results from the 2026 drilling programme will be released as they become available. The results will support continued geological modelling and evaluation of the potential for a maiden Mineral Resource Estimate at Nanoq.

About the Nanoq gold project
Nanoq is located in South Greenland, approximately 130km northeast of the Nalunaq gold mine, on the eastern flank of the Nanortalik Gold Belt. The project hosts multiple gold-bearing quartz vein systems within folded volcanic and sedimentary rocks and is being evaluated as a potential future high-grade gold source within Amaroq’s South Greenland portfolio.

In 2025, Amaroq completed 4,807m of diamond drilling across 27 holes, testing approximately 600m of strike within the Central Zone. The programme returned shallow high-grade intersections, including 187.4g/t Au over 1.5m and 19.6g/t Au over 4.9m, as well as broader mineralised intervals up to 9.0m. Mapping extended the interpreted Central Zone strike to approximately 1.5km and identified the parallel West 1 Zone approximately 500m to the west.

Qualified Person Statement
The technical information presented in this press release has been reviewed and approved by James Gilbertson, CGeol, Vice President Exploration of Amaroq and a Chartered Geologist with the Geological Society of London, who is a Qualified Person as defined by National Instrument 43-101. Mr Gilbertson has reviewed the provisional SGS metallurgical results and considers the information reliable for the purpose of this disclosure, subject to the qualifications described above.

-ENDS-

Enquiries:
Amaroq Ltd. C/O
Ed Westropp, Chief Corporate Development and Strategy Officer
+44 (0)7385 755711
ewe@amaroqminerals.com

Canaccord Genuity Limited (Corporate Broker)
James Asensio
Rory Blundell
Harry Rees
+44 (0) 20 7523 8000

Citigroup Global Markets Limited (Corporate Broker)
Andrew Miller-Jones
David Herring
+44 (0) 207 986 3463

Panmure Liberum Limited (Corporate Broker)
Scott Mathieson
Piers Shimwell
+44 (0) 20 7886 2500

Camarco (Financial PR)
Elfie Harkell
Rebecca Waterworth
Charlie Ramos
+44 (0) 20 3757 4980

Further Information:

About Amaroq
Amaroq’s focus is the identification, acquisition, exploration and development of gold and strategic metals in Greenland. The Company’s principal asset is the 100% owned and operated, producing Nalunaq Gold Mine.

Amaroq’s significant exploration portfolio includes opportunities in gold, copper, nickel and rare earth elements across South Greenland, as well as zinc, lead, silver, germanium and gallium at its West Greenland Hub centred on the past-producing zinc-lead-silver mine at Maarmorilik and the nearby Kangerluarsuk exploration licence, and the Minturn iron oxide copper gold prospect in northwest Greenland. The Company’s strategy is to unlock Greenland’s resource potential through continued exploration and development while building a responsible, full-cycle mining company, including through its Suliaq subsidiary, which provides mining services and logistics capabilities for Greenland’s developing mining sector, and Imeq ApS, Greenland’s first private hydroelectric project.

The Company is listed on the LSE Main Market and Nasdaq Iceland Main Market under the ticker AMRQ, and on OTCQX under AMRQF.

Inside Information

This announcement does not contain inside information.

ICG Enterprise Trust plc (the “Company”)

1 October 2026

Transaction in Own Shares

The Company announces that on 30 September 2026 it bought back 4940 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1377 pence per share.

Further details are set out below:

  • Number of shares held as treasury shares following settlement of this purchase: 3,372,500
  • Total shares in issue excluding treasury shares following settlement of this purchase: 60,181,692

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.